One of the many important stories grossly under-reported by the Mainstream Media is how for the past 18 months life insurance companies across the United States have been reporting significant increases in all-cause deaths in the 18-49 year-old age demographic, in addition to dramatic increases in miscarriages, Bell’s Palsy, and cancer.
Coinciding with these statistics are reports that regardless of the cause of death, right around November, 2021, coroners and embalmers across the country began noticing strange blood anomalies in these individuals, regardless of whether they had taken the COVID-19 vaccination or not.
As whistle-blower Dr. Theresa Long and other trade embalmers describe it, over a 16-18 month period at least every day a body or two would arrive containing these long white fibrous structures that look like calamari, which unlike traditional clots are literally starving the blood of oxygen the body needs to survive.
During hearings that Wisconsin Senator Ron Johnson has been conducting, data shows miscarriages have increased by 300% over their 5-year average, there was a 1000% increase in neurological disorders over 1 year affecting DOD pilots in the military, and that dramatic increases in cancer have been documented in 30 and 40 year-olds.
According to whistleblower Steve Kirsch, because the Covid vaccines were never fully tested, the toxic spike proteins contain many mechanisms that can allow cancer cells to mutate and ‘wake up’, making it one possible cause of this dramatic upsurge. “Around mid-2021 these clots started appearing that take the shape of the vessels they’re growing in, which disturbingly mirror the MRNA blueprint. During the testing phase the vaccine killed more people than the placebo did and it’s supposed to be the other way around. But at the CDC it’s like nobody wants to see this data because they don’t want to be confronted. They want plausible deniability.”
Originally it was going to take 53 years to obtain all the documents from pharmaceutical companies that tested the vaccines, but thanks to a court order these documents were supposed to be released by the end of 2022.
Through reports in the VAERS medical reporting system, a pediatrician with 43-years of experience witnessed 22 fetal demises in one month in 5 out of 6 vaccinated patients, and a 1200 fold increase in pregnant abnormalities. Heart related issues such as heart attack and stroke have witnessed a 40% increase.
Moreover, 68% of the population has been vaccinated with approximately 12,937 billion Covid vaccines administered to date, which brings us to the million dollar question: is it COVID-19 itself causing these spikes in mortality, or is it the vaccine?
Missed Reporting Deadlines
Pfizer was required by the U.S. and Food & Drug Administation (FDA) to conduct multiple studies on its vaccine after the FDA approved the shot in August 2021 because regulators determined that without the studies, there would not be sufficient data to assess the “known serious risks of myocarditis and pericarditis,” or heart inflammation and a related condition. Regulators were also concerned about the potential risk of subclinical myocarditis, or heart inflammation without typical symptoms.
The FDA told Pfizer to carry out six studies, with various deadlines for completion and reporting final results to the agency. The first final deadline arrived on Dec. 31, 2022.
Pfizer was required to submit a report on the study, which was to assess the incidence of subclinical myocarditis following administration of a third dose of Pfizer’s vaccine, or a booster shot, in people aged 16 to 30.
It’s unclear whether Pfizer met the deadline.
The company and the FDA did not respond to requests for comment, and neither have issued any information about the study or its results since the deadline passed. According to the FDA, Pfizer had until June 30, 2022, to complete the study and then another six months to prepare and submit the final results.
In a Dec. 8, 2022, memorandum explaining why the FDA authorized Pfizer’s bivalent booster without any clinical data, FDA officials noted that Pfizer was “conducting additional safety-related post-authorization/post-marketing studies for the PfizerBioNTech COVID-19 Vaccine, including post-marketing requirements to assess known serious risks of myocarditis and pericarditis and an unexpected serious risk of subclinical myocarditis..”
‘Shouldn’t Have to Ask’
The results of the study should be shared promptly, according to Jessica Adams, a former regulatory officer at the FDA. “We shouldn’t have to ask or demand this information. We should expect that it’d be promptly shared by default,” Adams wrote on Twitter.
Dr. Janet Woodcock, the agency’s principal deputy director, told Adams in an email that the FDA is “not allowed to comment on potential actions on regulated products.” It’s not clear how reporting results on a study relates to potential regulatory actions.
In light of the growing amount of evidence related to post-vaccination adverse events, some others are questioning the FDA’s delay in sharing information on the study.
“Why are FDA officials dragging their feet on making Pfizer’s prospective study data on subclinical myocarditis available to the public when evidence has been published in the medical literature that Pfizer’s pre-EUA clinical trials revealed ‘a 36 percent higher risk of serious adverse events in vaccinated participants in comparison to placebo recipients,'” Barbara Loe Fisher, co-founder and president of the National Vaccine Information Center responded via e-mail.
She was citing a reanalysis of the original trial data that found vaccinated participants had a higher risk of serious adverse events. “With 79 percent of Americans having received at least one COVID shot and so many vaccinated young adults, especially physically fit athletes suffering heart attacks and sudden deaths, public health officials should insist that the company with the biggest market share of the COVID vaccine business in the U.S. be completely transparent about what it knows about the biological mechanisms of heart inflammation induced by the mRNA COVID vaccine Pfizer maintains is both safe and effective,” Fisher added.
Warning
The FDA did add a warning about myocarditis following Pfizer and Moderna vaccination to patient and health care provider fact sheets in June 2021. Both vaccines utilize messenger RNA (mRNA) technology. Prospective vaccine recipients were told the risk of myocarditis was increased after vaccination, particularly after the second dose of the two-dose primary series. If certain symptoms appeared after vaccination, such as chest pain or shortness of breath, people were told to immediately seek medical care.
U.S. authorities, and some officials elsewhere, have since acknowledged that the vaccines cause heart inflammation. “The current evidence supports a causal association between mRNA COVID-19 vaccination and myocarditis and pericarditis,” Dr. Tom Shimabukuro, a top CDC official, said during a meeting in 2022.
Some cases of the post-vaccination inflammation have ended in death. Some 5,163 reports of post-vaccination myocarditis, pericarditis, or myopericarditis have been filed with the Vaccine Adverse Event Reporting System (VAERS), a passive early warning system that alerts officials to possible side effects from vaccines. The reports don’t prove a connection with a vaccine but are an undercount of the true number of cases, research has found and authorities have acknowledged.
More than 800,000 other adverse events following receipt of the Pfizer vaccine have been lodged with the system.
Pathologists at The Mount Sinai Hospital, at the epicenter of the COVID-19 global pandemic, have prepared one of the largest, most comprehensive analysis of autopsies of COVID-19 victims to date, revealing many complex new details about the disease. The analysis was released on the preprint server MedRxiv.
“An essential contribution of pathology is the understanding of the biology of the disease and the range of organ damage, and for this reason, we decided to uncompromisingly perform as many autopsies as possible,” said Carlos Cordon-Cardo, MD, PhD, Irene Heinz Given and John LaPorte Given Professor and Chair of the Lillian and Henry M. Stratton-Hans Popper Department of Pathology, Molecular and Cell-Based Medicine, and co-author of the study.
“Post-mortem examinations (autopsies) are the gold standard for the elucidation of the underlying pathophysiology of disease. Despite a rapidly growing body of literature focusing on the clinical impact and molecular microbiology of SARS-CoV-2, autopsy studies have comparatively been few and far between,” said Mary Fowkes, MD, PhD, Director of the Autopsy Service, and senior author of the paper. SARS-CoV-2 is the virus that causes COVID-19.
To date, the team has performed more than 90 autopsies on deceased COVID-19 patients at The Mount Sinai Hospital. The published work analyzes the first 67. Gross anatomical findings were combined with the clinical history and laboratory data for all 67 patients.
COVID-19 was initially conceptualized as a primarily respiratory illness, but the Mount Sinai analysis laid out in detail that it also causes damage to the thin layer of cells that line blood vessels (endothelium), which underlies the clotting abnormalities and hypoxia observed in severely ill patients who develop multi-organ failure that leads to death in some patients.
They conclude: “The lungs in nearly all cases showed diffuse damage to the alveoli, the small sacs where oxygen and carbon dioxide are exchanged with the blood. This damage is the typical microscopic evidence of clinical acute respiratory distress syndrome (ARDS), with most cases showing fibrin (a fibrous, non-globular protein involved in the clotting of blood) and/or platelet thrombi, or clots, to varying extents. However, the totality of findings in the autopsy series as a whole, with blood clots in multiple other organ systems—most notably the brain, kidney, and liver—reflects endothelial damage as an underlying process, which would also correlate with the activation of the coagulation cascade and persistent elevation of blood markers of inflammation.”
Moderna Studies
The FDA also required Moderna to conduct post-approval studies after approving the company’s shot in early 2022. Moderna was told to carry out six studies, the same number as Pfizer, focusing on assessing the incidence of myocarditis and pericarditis, the long-term impact of myocarditis, and the occurrence of subclinical myocarditis.
Two studies were due to be completed by Dec. 31, 2022, but the deadlines for submission of the results to the FDA aren’t until June 30, 2023.
Other deadlines for the Moderna and Pfizer studies stretch months or even years into the future, including one in 2025 and one in 2028.
In these early days of 2023 another interesting fact surfaced prior to our publication deadline: the Japanese over 65 have done their best to reduce Japan’s 612-million-dose stockpile of mRNA jabs, with 3rd, 4th, and 5th jab rates of 91%, 82.5%, and 56%, respectively. But unfortunately, Japan has started 2023 by reporting its highest ever daily Covid death tolls. During the booster era starting in early 2022, each wave has been noticeably higher than the last.
The REVIEW also contacted the Saginaw County Health Department to see if they had any data on increased mortality rates from hospitals in the Great Lakes Bay Region over the past 18-months, but according to Director Christina Harrington, “Unfortunately we do not have that data accessible at a local health department. These findings that you are referring to would likely be captured during autopsies performed and perhaps noted in some reports - you may want to connect with the Medical Examiner’s office.”
Pfizer and BioNTech have both raked in $37 billion in revenue in 2021 alone from the COVID-19 vaccine, while Moderna made $17.7 billion the same year (and has recently announced a plan to hike the price of the vaccine by approximately 400%
It was also revealed in the 5th dump of The Twitter Files that BioNTech, which developed Pfizer’s vaccine, reached out to Twitter requesting they directly censor users tweeting at them to ask for low cost vaccines.
Comments (0)
Login to comment